<SEC-DOCUMENT>0001567619-20-020897.txt : 20201210
<SEC-HEADER>0001567619-20-020897.hdr.sgml : 20201210
<ACCEPTANCE-DATETIME>20201210191915
ACCESSION NUMBER:		0001567619-20-020897
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20201210
FILED AS OF DATE:		20201210
DATE AS OF CHANGE:		20201210

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			YAO TONY DUNG LING
		CENTRAL INDEX KEY:			0001771680

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39782
		FILM NUMBER:		201381807

	MAIL ADDRESS:	
		STREET 1:		C/O PRECISION BIOSCIENCES, INC.
		STREET 2:		302 EAST PETTIGREW STREET, SUITE A-100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27701

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			4D Molecular Therapeutics Inc.
		CENTRAL INDEX KEY:			0001650648
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				473506994
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		5858 HORTON STREET #455
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		5105052680

	MAIL ADDRESS:	
		STREET 1:		5858 HORTON STREET #455
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	4D Molecular Therapeutics Inc
		DATE OF NAME CHANGE:	20150811
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>doc1.xml
<DESCRIPTION>FORM 3
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2020-12-10</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001650648</issuerCik>
        <issuerName>4D Molecular Therapeutics Inc.</issuerName>
        <issuerTradingSymbol>FDMT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001771680</rptOwnerCik>
            <rptOwnerName>YAO TONY DUNG LING</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O 4D MOLECULAR THERAPEUTICS INC.</rptOwnerStreet1>
            <rptOwnerStreet2>5858 HORTON STREET #455</rptOwnerStreet2>
            <rptOwnerCity>EMERYVILLE</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94608</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable></nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Series B Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>17.46</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>2864</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The preferred stock has no exercisable or expiration date.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ August J. Moretti, Attorney-in-Fact for Tony Dung Ling Yao</signatureName>
        <signatureDate>2020-12-10</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>poa_yao.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: seriously
         Document created using EDGARfilings PROfile 7.3.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; margin-bottom: 18pt; font-weight: bold;">POWER OF ATTORNEY</div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;">KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of (i)&#160;the Chief Executive
      Officer of 4D Molecular Therapeutics, Inc., a Delaware corporation (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;), who is currently David Kirn, (ii)&#160;the
      Company&#8217;s Chief Financial Officer, who is currently August&#160;J. Moretti, and (iii)&#160;the Company&#8217;s General Counsel and their respective successors, signing singly, with full power of substitution, as the undersigned&#8217;s true and lawful attorney-in-fact to:</div>
    <table cellspacing="0" cellpadding="0" id="z39088729b5604db189563799471fa1d4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; margin-top: 12pt;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>execute for and on behalf of the undersigned, in the undersigned&#8217;s capacity as an officer and/or director of the Company, Forms&#160;3, 4 and 5 (including amendments
              thereto) in accordance with Section&#160;16(a) of the Securities Exchange Act of 1934 and the rules and regulations thereunder and a Form ID, Uniform Application for Access Codes to File on EDGAR;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z5ed5599281ce4ccea889ed70f26a0a71" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; margin-top: 12pt;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms 3, 4 or 5 or Form ID and
              timely file such forms (including amendments thereto) and application with the United States Securities and Exchange Commission and any stock exchange or similar authority; and</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z5b2a0ac6910445dfbe1db6942c83ae19" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; margin-bottom: 12pt; margin-top: 12pt;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(3)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest
              of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and
              conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;">The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and
      every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power
      of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers
      herein granted.&#160; The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with
      Section&#160;16 of the Securities Exchange Act of 1934.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;">The undersigned agrees that each such attorney-in-fact herein may rely entirely on information furnished orally or
      in writing by the undersigned to such attorney-in-fact.&#160; The undersigned also agrees to indemnify and hold harmless the Company and each such attorney-in-fact against any losses, claims, damages or liabilities (or actions in these respects) that
      arise out of or are based upon any untrue statements or omission of necessary facts in the information provided by the undersigned to such attorney-in fact for purposes of executing, acknowledging, delivering or filing Forms 3, 4 or 5 (including
      amendments thereto) or Form ID and agrees to reimburse the Company and such attorney-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;">This Power of Attorney supersedes any power of attorney previously executed by the undersigned regarding the
      purposes outlined in the first paragraph hereof ("<font style="font-weight: bold; font-style: italic;">Prior Powers of Attorney</font>"), and the authority of the attorneys-in-fact named
      in any Prior Powers of Attorney is hereby revoked.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;">This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file
      Forms&#160;3, 4 or 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier (a)&#160;revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (b)&#160;superseded by a
      new power of attorney regarding the purposes outlined in the first paragraph hereof dated as of a later date.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 24pt;">IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 28 day of
      September, 2019.</div>
    <div style="margin-left: 211.5pt; margin-bottom: 24pt;"><u>/s/ Tony Dung Ling Yao</u><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 243pt">&#160;</font><br>
        <font style="font-weight: bold; font-variant: small-caps;">Tony Dung Ling Yao</font></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
